Alteration in the Recommended Dosing Schedule for Risperidone

Luchins, Daniel J.; Klass, David; Hanrahan, Patricia; Malan, Randy; Harris, Jennifer

doi:10.1176/ajp.155.3.365

Cited by 20 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All these data seem to suggest that it may be apparently difficult to establish RSP optimal individual oral dosage and dose titration in some cases [19]. In any case it seems interesting that the suggested minimal effective dose of RSP based on PET-measured D2 and 5HT2A receptor occupancy is 4 mg/day [27].…”

Section: Discussionmentioning

confidence: 99%

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

et al. 2001

View full text Add to dashboard Cite

Twenty-four chronic schizophrenic outpatients with a mean age of 37.21 years +/- 9.96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4.46 mg/die +/- 1.30 SD, mean 0.06 mg/kg +/- 0.01 SD) for a year. Clinical evaluation was assessed with the Brief Psychiatric Rating Scale (BPRS), Positive and Negative Symptoms Scale (PANSS), Extrapyramidal Side Effects Rating Scale (EPSE) and a checklist for Anticholinergic Side Effects (ACS) at T0, then after 1 (T1), 2 (T2), 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months. RSP and 9-hydroxy-risperidone (9OH-RSP) plasma levels were determined at T12 by the HPLC method. BPRS and PANSS mean values showed a significant improvement during the study. No correlation between RSP dosage (mg/kg) and RSP, 9OH-RSP plasma levels or active moiety resulted. A positive correlation between age and active moiety was observed. A positive correlation between RSP and 9OH-RSP plasma levels was observed. A curvilinear relationship between active moiety and PANSS improvement (%) was observed. Patients with the higher PANSS amelioration showed RSP + 9OH-RSP plasma levels ranging from 15 to 30 ng/mL. RSP seems to be quite an effective drug. It seems, however, difficult to devise appropriate dose schedules and plasma level determination seems to be necessary in some cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Randomized studies comparing olanzapine and risperidone in schizophrenia treatment have had mixed results regarding their relative efficacy [14–16]. Risperidone's safety profile has resulted in recommendations that risperidone doses be kept below 6 mg per day [17–19], whereas olanzapine has been associated with more weight gain than risperidone [20]. The one randomized comparison of olanzapine ( n = 172) and risperidone ( n = 167) that evaluated maintenance of response found an advantage for olanzapine (88% vs. 68% maintained response until week 28, Kaplan–Meyer P = .001) [14].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population

et al. 2004

View full text Add to dashboard Cite

Total costs of schizophrenia care associated with olanzapine, risperidone, or haloperidol were similar, but component costs differed. Relative to risperidone or haloperidol, olanzapine may have a higher acquisition cost, but may decrease inpatient costs and be associated with more optimal medication use patterns. Use of risperidone may also increase pharmacy costs and be associated with greater persistence, relative to haloperidol.

show abstract

“…De 1997 até 2001, a dose média de risperidona usada para pacientes internados no sistema estadual de Nova York diminuiu de 7,1 para 4,9 mg/dia . Adicionalmente, com base muma pesquisa retrospectiva, uma titulação menos rápida de risperidona (de 0,5 a 2 mg/dia) foi recomendada para manter os pacientes aderentes aos seus medicamentos (Luchins et al, 1998). Por outro lado, as doses de olanzapina no sistema do Estado de Nova York para os pacientes internados aumentou.…”

Section: Escolha Do Medicamento Antipsicóticounclassified

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo

Falkai¹,

Wobrock²,

Lieberman³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoEstas diretrizes para o tratamento biológico da esquizofrenia foram desenvolvidas pela Força-Tarefa da Federação Mundial das Sociedades de Psiquiatria Biológica (World Federation of Societies of Biological Psychiatry, WFSBP). A meta fixada durante o desenvolvimento destas diretrizes foi rever sistematicamente todas as evidências disponíveis referentes ao tratamento da esquizofrenia, tanto no âmbito clínico como científico, e chegar a um consenso sobre as principais recomendações para a prática psiquiátrica. Estas diretrizes são destinadas a todos os médicos que atendem e tratam de pacientes portadores de esquizofrenia. Os dados usados para desenvolver estas diretrizes foram extraídos primariamente de vários painéis e diretrizes nacionais de tratamento para esquizofrenia, assim como de metanálises, revisões e estudos clínicos randomizados sobre a eficácia do tratamento farmacológico e de outras intervenções terapêuticas biológicas, identificadas por uma busca nas bases de dados MedLine e Biblioteca Cochrane. A literatura identificada foi avaliada no que diz respeito à solidez das evidências a favor da eficácia de uma dada intervenção e,

show abstract

Alteration in the Recommended Dosing Schedule for Risperidone

Abstract: These findings suggest that the recommended dose schedule should be altered to one that recommends a less rapid titration (over 6 days to a week) and that the dose increments consist of 0.5-2 mg/day.

Cited by 20 publications

References 4 publications

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo

Contact Info

Product

Resources

About